Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
Category: Company News
World Pharma Today || Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
European Pharmaceutical manufacturer || Paradigm4 and Alnylam partnership to accelerate RNAi- based drug discovery
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the pace and productivity of Alnylam’s RNAi therapeutics pipeline.
LABIOTECH || Partnership between Paradigm4 and Alnylam accelerates drug target discovery
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Biocompare || Introduction to Spatial Metabolomics
Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
IPI || Why the right approach to data management will enable the potential of small-molecule RNA sodifiers as drug targets to be fulfilled
Over the past 5 decades or so, the growing understanding that RNA can influence protein function through routes other than direct translation has opened the prospect of discovering small molecules for tackling diseases in novel ways.
Biocompare || Peptidomics: Methods in the search for molecular disease signatures
Peptides play important roles in human physiology. They present as intact peptides or can arise from protein degradation. Regardless of the source, peptidomics—the characterization of intact peptides in a biological sample—is fast emerging as an approach to uncover another layer in human health and disease.
Bio-IT World || Lessons From the Recent HCA 2022 General Meeting: Applying Single-Cell Data to Clinical Decision Making
The recent Human Cell Atlas (HCA) 2022 General Meeting, hosted in Vienna, Austria, provided a great opportunity for me to catch up on progress towards the HCA’s goal of mapping every cell type in the human body. I also got the chance to hear presentations that either highlighted new insights gleaned from HCA data or described the outcomes from ongoing collaborations between research groups.
Clinical Laboratory || Paradigm4 introduces Precision Cell Atlas for REVEAL: SingleCell app
Paradigm4 has introduced the ‘Precision Cell Atlas’ as an integral component of its REVEAL: SingleCell app. The Precision Cell Atlas enables scientists to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives and explicitly saving them for collaboration, reuse, and regulatory filings
Pharma’s Almanac || What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”